• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 180 Life Sciences Corp. (Amendment)

    2/7/22 4:30:32 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email
    SC 13G/A 1 ea155010-13ga1nancha_180life.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    180 LIFE SCIENCES CORP.

     (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE

    (Title of Class of Securities)

     

    68236V104

    (CUSIP Number)

     

    December 31, 2021

     (Date of Event Which Requires Filing this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 68236V104 13G Page 2 of 5

     

    1  

    Name of Reporting Persons

     

    Jagdeep Nanchahal

    2  

    Check the Appropriate Box if a Member of a Group

    (see instructions)

    (a) ☐

    (b) ☐

    3  

    SEC Use Only

     

     

    4  

    Citizenship or Place of Organization

     

    British citizen

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with:

      5  

    Sole Voting Power

     

    1,520,564

      6  

    Shared Voting Power

     

    -0-

      7  

    Sole Dispositive Power

     

    1,520,564

      8  

    Shared Dispositive Power

     

    -0-

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,520,564

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)  ☐

     

     

    11  

    Percent of Class Represented by Amount in Row 9

     

    4.5%(1)

    12  

    Type of Reporting Person (see instructions)

     

    IN

      

    (1)Based on 34,016,456 shares of Common Stock of the Issuer outstanding as of November 12, 2021, as set forth on the cover page of the Issuer’s Quarter Report on Form 10-Q for the quarter ended September 30, 2021.

     

     

     

     

    CUSIP No. 68236V104 13G Page 3 of 5

     

    SCHEDULE 13G

     

    This Schedule 13G/A (Amendment No. 1)(this “Schedule 13G”) is being filed on behalf of Mr. Jagdeep Nanchahal, an individual, in connection with the common stock, $0.0001 par value per share (“Common Stock”) of 180 Life Sciences Corp., a Delaware corporation (the “Issuer”). Mr. Nanchahal is a consultant of the Issuer and the Chairman of the Issuer’s Clinical Advisory Board.

     

    Item 1(a) Name of Issuer.
       
      180 Life Sciences Corp.

     

    Item 1(b) Address of Issuer’s Principal Executive Offices.
       
     

    3000 El Camino Real, Bldg. 4, Suite 200

    Palo Alto, CA 94306

     

    Item 2(a) Name of Person Filing.
       
      Mr. Jagdeep Nanchahal
       
    Item 2(b) Address of Principal Business Office, or, if none, Residence.
       
      11 Terrett Avenue, Oxford, UK OX3 8FE

     

    Item 2(c) Citizenship or Place of Organization.

     

      Mr. Nanchahal is a British citizen.

     

    Item 2(d) Title of Class of Securities.
       
      Common stock, $0.0001 par value per share (the “Common Stock”).

     

    Item 2(e) CUSIP Number.
       
      68236V104

       

    Item 3 Reporting Person.

     

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

      

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

     

    CUSIP No. 68236V104 13G Page 4 of 5

       

    Item 4 Ownership.

     

    (a)Amount beneficially owned: Mr. Nanchahal is the beneficial owner of 1,520,564 shares of Common Stock.

     

    (b)Percent of class: Mr. Nanchahal is the beneficial owner of 4.5% of the outstanding shares of Common Stock of the Issuer. This percentage is determined by dividing 1,520,564, by 34,016,456 shares, the number of outstanding shares of the Issuer as of November 12, 2021.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 1,520,564

     

    (ii)shared power to vote or to direct the vote: -0-

     

    (iii)sole power to dispose or to direct the disposition of: 1,520,564

     

    (iv)shared power to dispose or to direct the disposition of: -0-

     

    Item 5 Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6 Ownership of More Than Five Percent on Behalf of Another Person.
       
      Inapplicable.

     

    Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.
       
      Inapplicable.

     

    Item 8 Identification and Classification of Members of the Group.
       
      Inapplicable.

     

    Item 9 Notice of Dissolution of Group.
       
      Inapplicable.

     

    Item 10 Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 68236V104 13G Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 7, 2022

     

     

    /s/ Jagdeep Nanchahal

      Jagdeep Nanchahal

     

     

     

     

     

     

    Get the next $ATNF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    12/18/23 4:15:16 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

    Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

    9/15/21 7:48:59 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Financials

    Live finance-specific insights

    View All

    180 Life Sciences Corp. - Corporate Updates

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

    10/3/24 8:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/18/25 5:27:22 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Rudisill Mcandrew

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 5:20:03 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Heter Crystal Jane

    3 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 4:15:12 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    10/18/24 5:00:02 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    2/14/24 3:27:19 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by 180 Life Sciences Corp.

    SCHEDULE 13D/A - ETHZilla Corp (0001690080) (Subject)

    8/18/25 5:22:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    8/18/25 8:01:32 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K/A - ETHZilla Corp (0001690080) (Filer)

    8/18/25 6:33:10 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy

    Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025 Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the

    8/18/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences (ETHZilla) Holds 82,186 ETH

    Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, ETHZilla holds approximately $238 million in USD cash equivalents. "At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and

    8/12/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif., Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggregate principal amount of senior secured convertible notes due 2028 (the "Convertible Notes") in a private offering to an institutional investor on August 8, 2025. The Company intends to us

    8/11/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    View All

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

    PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

    12/12/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

    PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

    12/4/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care